Goshi Oda,Tsuyoshi Nakagawa,Hiroki Mori,Iichiro Onishi,Tomoyuki Fujioka,Mio Mori,Kazunori Kubota,Ryoichi Hanazawa,Akihiro Hirakawa,Toshiaki Ishikawa,Kentaro Okamoto,Hiroyuki Uetakesszsz
Goshi Oda,Tsuyoshi Nakagawa,Department of Breast Surgery,Tokyo Medical and Dental University,Tokyo 1138519,Japan
Hiroki Mori,Department of Plastic and Reconstructive Surgery,Tokyo Medical and Dental University,Tokyo 1138519,Japan
Iichiro Onishi,Department of Pathology,Tokyo Medical and Dental University,Tokyo 1138519,Japan
Tomoyuki Fujioka,Mio Mori,Kazunori Kubota,Department of Radiology,Tokyo Medical and Dental University,Tokyo 1138519,Japan
Ryoichi Hanazawa,Akihiro Hirakawa,Department of Clinical Biostatistics,Tokyo Medical and Dental University,Tokyo 1138519,Japan
Toshiaki Ishikawa,Kentaro Okamoto,Hiroyuki Uetakesszsz,Department of Specialized Surgeries,Tokyo Medical and Dental University,Tokyo 1138519,Japan
Abstract BACKGROUND With sentinel node metastasis in breast cancer (BC) patients,axillary lymph node (ALN) dissection is often omitted from cases with breast-conserving surgery. Omission of lymph node dissection reduces the invasiveness of surgery to the patient,but it also obscures the number of metastases to non-sentinel nodes. The possibility of finding ≥ 4 lymph nodes (pN2a/pN3a) preoperatively is important given the ramifications for postoperative treatment.AIM To search for clinicopathological factors that predicts upstaging from N0 to pN2a/pN3a.METHODS Patients who were sentinel lymph node (SLN)-positive and underwent ALN dissection between September 2007 and August 2018 were selected by retrospective chart review. All patients had BC diagnosed preoperatively as N0 with axillary evaluation by fluorodeoxyglucose (FDG) positron emission tomography/computed tomography and ultrasound (US) examination. When suspicious FDG accumulation was found in ALN,the presence of metastasis was reevaluated by second US. We examined predictors of upstaging from N0 to pN2a/pN3a.RESULTS Among 135 patients,we identified 1-3 ALNs (pN1) in 113 patients and 34 ALNs (pN2a/pN3a) in 22 patients. Multivariate analysis identified the total number of SLN metastasis,the maximal diameter of metastasis in the SLN (SLNDmax),and FDG accumulation of ALN as predictors of upstaging to pN2a/pN3a.CONCLUSION We identified factors involved in upstaging from N0 to pN2a/pN3a. The SLNDmax and number of SLN metastasis are predictors of ≥ 4 ALNs (pN2a/pN3a) and predictors of metastasis to nonsentinel nodes,which have been reported in the past. Attention should be given to axillary accumulations of FDG,even when faint.
Key Words: Breast cancer; Axillary lymph node metastasis; Positron emission tomography/computed tomography; Sentinel lymph node; Predictive factors of lymphnode metastasis; Standardized uptake value max; Diameter of sentinel lyphonode metastasis
Sentinel lymph node (SLN) biopsy is usually performed in N0 cases. If SLN biopsy yields a positive result,an axillary lymph node (ALN) dissection is performed. However,since the publication of findings from the American College of Surgeons Oncology Group (ACOSOG) Z-0011 trial,many cancer centers have been omitting ALN dissection from breast-conserving surgeries[1]. The problem with omitting axillary dissection is that the number of non-SLN metastases cannot be ascertained,which may lead to over or under-treatment with adjuvant chemotherapy and radiation therapy. For example,patients with pN2a [4-9 ALN metastases (ALNMs)] or pN3a (310ALNMs) need to be irradiated to not only the residual breast,but also the supraclavicular region after breast-conserving surgery. However,without knowing the number of metastases,no accurate decision on the need for irradiation can be made. Post-mastectomy radiation (PMRT) is also required for pN2a/N3a patients. Some reports have noted that PMRT after reconstruction impairs conformity[2-4]. Further analyses have shown that direct implants and autologous tissue reconstruction have fewer complications from PMRT[5,6]. The ability to predict the necessity of postoperative irradiation before surgery would affect surgical planning,including reconstructive surgery. A variety of factors and nomograms have been reported to allow preoperative prediction of the presence or absence of ALNMs[7-9],but few reports have examined factors predicting the presence of 34 ALNMs. Preoperative fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is reportedly excellent for predicting metastasis preoperatively and may have influenced the prediction of ALNMs in the present study. Although many papers have described predictors of non-SLN metastasis,few have rigorously assessed ALNM preoperatively using PET/CT. In this study,all patients were evaluated preoperatively by PET/CT,and cases with false-negative results on other imaging modalities were excluded. This is the first report to include the results of preoperative PET/CT and to examine results related to the upstaging of pN2a/pN3a.
A retrospective chart review was conducted for patients who were SLN-positive and underwent ALND between September 2007 and August 2018. All patients had breast cancer (BC) diagnosed preoperatively as N0 with axillary evaluation by PET/CT and ultrasound (US) examination. This study was conducted with approval from the institutional review board and with the informed consent of each patient. Axillary dissection was performed in all patients with SLN metastasis > 2 mm in diameter. In the case of total mastectomy,axillary dissection was performed for metastases > 0.2 mm in diameter. A flow chart of the eligible/included patients is shown in Figure 1.
A EUB-7500 scanner with a EUP-L54MA 9.75-MHz linear probe (Hitachi Medical Systems,Tokyo,Japan) or Aplio XG scanner with a PLT-805AT 8.0-MHz linear probe (Toshiba Medical Systems,Tochigi,Japan) was used for US examinations. If ultrasound or PET/CT findings were suspicious for metastatic lymph nodes,cytology was performed.
All patients were intravenously administered18F-FDG (3.7 MBq/kg; 0.1 mCi/kg) after a minimum 4-h fasting period. Next,whole-body images were routinely obtained using a PET/CT system (Aquiduo; Toshiba Medical Systems,Tokyo,Japan). In addition,CT was performed using the following parameters: pitch factor,0.938; gantry rotation time,0.5 s; table time,30 mm/s; auto-exposure control (SD20),120 kVp; and slice thickness,2.0 mm. Notably,contrast media were not used for CT examinations. Approximately 60 min after18F-FDG administration,whole-body PET was performed using the following parameters: emission time per bed,2 min; bed positions,7-8; slice thickness,3.375 mm; and matrix,128 × 128.
In the present study,18F-FDG-PET/CT findings at each examination were assessed using a consensus reading by two breast radiologists (T.F. with 14 years of experience in breast imaging; M.M. with 10 years of experience in breast imaging). We performed visual analysis of primary lesions and ALNs without defining a cut-off value. Of note,lesions with an18F-FDG uptake value higher than that of the background tissue were defined as FDG-positive.
All specimens were analyzed by pathologists from our institution,and specimens were considered estrogen receptor (ER) positive on immunohistochemistry (IHC) for staining rates higher than 10%. For human epidermal growth factor receptor 2 (HER2) values,and IHC result of 3+ was defined as BC with strong,complete membrane staining observed in at least 10% of tumor cells. For HER2 overexpression of 2+,gene amplification with fluorescence in situ hybridization was performed in this study.
Differences in proportions of categorical data were tested using Fisher’s exact probability test. Unless otherwise indicated,significant differences among mean values of numerical data were analyzed using Mann-Whitney test. Relationships between the size of SLN metastases and the number of ALNMs were measured using Spearman rank correlation analysis,which can have a magnitude ranging from 0 to 1,with 0 denoting no correlation at all and 1 denoting complete correlation. Predictors of upstaging to pN2a/pN3a were determined by univariate and multivariate logistic regression analyses. Values ofP< 0.05 were regarded as statistically significant. All statistical analyses were performed using EZR (Saitama Medical Center,Jichi Medical University,Saitama,Japan),a graphical user interfaces for R (The R Foundation for Statistical Computing,Vienna,Austria)[10]. More precisely,EZR is a modified version of R Commander designed to add statistical functions frequently used in biostatistics.
We retrospectively analyzed 135 BC patients who were SLN-positive and had undergone ALN dissection. FDG-PET/CT was performed in all cases preoperatively. The detailed clinicopathological characteristics of subjects are summarized in Table 1. Among these,113 patients showed 1-3 ALNMs (pN1) and 22 patients had 34 ALNMs (pN2a/pN3a). FDG accumulation in ALNs was found on PET/CT in 19 cases (14.1%). The mean standardized uptake value (SUV) max was 1.48 (range,0.8-2.0). Preoperative PET/CT showed accumulation in the ALNs,and second-look US was performed in cases where metastasis could not be ruled out. The mean number of excised SLNs was 1.6 (range,1-5) and the mean number of SLN metastasis was 1.2 (range,1-3). The median maximal diameter of metastasis in the SLN (SLNDmax) was 3 mm. The correlation between the SLNDmax and the number of ALNMs is shown in Figure 2. A strong correlation was identified between SLNDmax and the number of ALNMs (P< 0.001). We measured the cut-off value for the SLNDmax from the receiver operating characteristic (ROC) curve and the cut-off value for upstaging from N0 to pN2a/pN3a was set at 5 mm (area under the curve: 0.873; 95%CI: 0.808-0931) (Figure 3). Table 2 shows a comparison between pN1 and pN2a/pN3a.
To search for risk factors for upstaging to pN2a/N3a,univariate and multivariate analyses were performed for associations with clinicopathological factors in two groups of pN1 and pN2a/N3a cases. Invasive diameter at the primary site,number of SLN metastasis,FDG accumulation in ALNs,and SLNDmax were associated with upstaging to pN2a/pN3a,but age,ER status,HER 2 status,tumor grade,and SUVmax at the primary site were not (Table 3).
Multivariate logistic regression analysis of clinicopathologic factors was used to examine risk factors for upstaging to pN2a/pN3a. The number of SLN metastasis,SLNDmax,and FDG accumulation in ALNs were associated with upstaging (Table 3).
The ACOSOG Z-0011 trial concluded that ALN dissection is not always necessary for women undergoing breast-conserving surgery with 1-2 positive SLNs[1]. However,the overall number of ALNMs represents crucial clinical information. Although avoidance of ALN dissection reduces the degree of surgical invasiveness of a procedure,the number of ALNMs cannot be ascertained. If more than 4 metastatic lymph nodes are present,radiation to the breast or chest wall as well as to the supraclavicular area is necessary[11]. Thus,not knowing the number of ALNMs may lead to over-or under-treatment with radiation therapy postoperatively. The presence or absence of postoperative radiation may also affect the choice of reconstructive technique. Radiation during the insertion of an expander is associated with a greater risk of complications,while radiation after implant placement or to autologous tissue is reported to have fewer complications[2,3]. Pre- and postoperative prediction of the number of ALNMs affects not only the optimal extent of axillary dissection,but also the choice of radiotherapy and,indirectly,reconstruction methods. In the present study,we searched for predictors of upstaging from clinical N0 to pN2a/pN3a using factors identified pre- or intraoperatively,including FDGPET/CT. This imaging modality is generally considered useful in searching for ALNMs[12]. However,few reports have specified whether preoperative PET/CT was performed when examining factors predicting non-SLN metastasis. As a result of examining various factors for upstaging,we extracted SLNDmax,mild accumulation of FDG in the axilla,and the number of SLN metastasis. The SLNDmax and the number of SLN metastasis have been reported in the past as predictors of metastasis to non-SLNs[13-16]. This is the first study to show that these factors are also important in upstaging from N0 to pN2a/pN3a. Various cut-offs for the SLNDmax have been reported as a predictor of non-SLN metastasis,and we used ROC curves in our search. As a result,the predictor for upstaging from N0 to pN2a/pN3a was set at 5 mm. If the number of SLN metastasis is large (that is,two or more) or the diameter of metastasis is large (more than 5 mm),or if FDG accumulation in the axilla is mild even if no metastases have been confirmed,irradiation to the chest wall and supraclavicular region may need to be considered even in cases where axillary dissection has been omitted. PET/CT is often performed preoperatively for different cancers. On the other hand,findings from this modality are reportedly less significant for low-stage BC,given the low likelihood of distant metastasis. Some reports have suggested that SUV at the primary site may offer a useful predictor of metastasis to non-SLNs[17]. Uedaet al[18] evaluated ALNMs using PET/CT and reported low sensitivity but high specificity. In the present study,we found PET/CT to be useful in predicting multiple ALNMs,but the positive predictive value was not particularly high (57.9%). Many questions remain unanswered,such as the optimal cutoff value for integrated SUV,the influence of the histological type of the primary tumor,and the suitable timing of biopsy.
Table 1 Background characteristics of all patients
Table 2 Comparison between pN1 and pN2a/pN3a
Further accumulation and analysis of cases are needed. Institutions that aggressively omit axillary dissection should be aware of the dangers of remaining ignorant of the number of ALNMs when multiple risk factors are identified pre- or intraoperatively.
Table 3 Uni- and multivariate logistic regression analysis of risk factors associated with upstaging pN2a/pN3a
Figure 2 Correlation between the maximal diameter of metastasis in the sentinel lymph nodes and number of axillary lymph node metastases.
The present study investigated factors predictive of upstaging from clinical N0 to pN2a/pN3a. Factors such as the number of metastases and SLNDmax,which have previously been reported as predictors of metastasis to non-SLNs,were also useful in predicting upstaging to pN2a/pN3a and emphasized the utility of FDG-PET/CT. The only factor that predicts preoperatively,but not intraoperatively,is the result of FDG-PET/CT.
Figure 3 Cut-off value for the maximal diameter of metastasis in the sentinel lymph node from the receiver operating characteristic curve and cut-off for upstaging from N0 to pN2a/pN3a set to 5 mm (area under the curve: 0.873,95%CI: 0.808-0931).
With sentinel node metastasis in breast cancer (BC) patients,axillary lymph node (ALN) dissection is often omitted from cases with breast-conserving surgery. Omission of lymph node dissection reduces the invasiveness of surgery to the patient,but it also obscures the number of metastases to non-sentinel nodes.
The possibility of finding ≥ 4 lymph nodes (pN2a/pN3a) preoperatively is important given the ramifications for postoperative treatment.
The purpose of this study is to search for clinicopathological factors that predict upstaging from N0 to pN2a/N3a.
Patients who were SLN-positive and underwent ALN dissection between September 2007 and August 2018 were selected by retrospective chart review. All patients had BC diagnosed preoperatively as N0 with axillary evaluation by fluorodeoxyglucose (FDG) positron emission tomography/computed tomography and ultrasound (US) examination. When suspicious FDG accumulation was found in ALN,the presence of metastasis was reevaluated by second US. We examined predictors of upstaging from N0 to pN2a/pN3a.
Among 135 patients,we identified 1-3 ALNs (pN1) in 113 patients and 34 ALNs (pN2a/pN3a) in 22 patients. Multivariate analysis identified the total number of SLN metastasis,the maximal diameter of metastasis in the SLN (SLNDmax),and FDG accumulation of ALN as predictors of upstaging to pN2a/pN3a.
We identified factors involved in upstaging from N0 to pN2a/pN3a. The SLNDmax and number of SLN metastasis are predictors of ≥ 4 ALNs (pN2a/pN3a) and predictors of metastasis to non-sentinel nodes,which have been reported in the past. Attention should be given to axillary accumulations of FDG,even when faint.
It is somewhat possible to predict upstaging to pN2a/pN3a by searching for clinicopathological factors
FOOTNOTES
Author contributions:Oda G contributed to the conceptualization,methodology,software,validation,formal analysis,visualization and writing-original draft preparation; Hanazawa R,Hirakawa A contributed to the statistical checks; Oda G,Nakagawa T,Mori H,Onishi I,Fujioka T,Mori M,and Kubota K contributed to the investigation,resources; Oda G and Mori M contributed to the data curation; Nakagawa T contributed to the writing-review and editing; Okamoto K,Ishikawa T and Uetakesszsz H contributed to the supervision; All authors have read and agreed to the published version of the manuscript.
Institutional review board statement:The study was conducted according to the guidelines of the Declaration of Helsinki,and approved by the Ethics Committee of Tokyo Medical and Dental University,Tokyo,Japan (M2019-137,date of approval: 19 September 2019).
Informed consent statement:All study participants,or their legal guardian,provided informed written consent prior to study enrollment.
Conflict-of-interest statement:The authors declare no conflict of interest.
Data sharing statement:Technical appendix,statistical code,and dataset available from the corresponding author at odasrg2@tmd.ac.jp.
STROBE statement:The authors have read the STROBE Statement checklist of items,and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license,which permits others to distribute,remix,adapt,build upon this work non-commercially,and license their derivative works on different terms,provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Country/Territory of origin:Japan
ORCID number:Goshi Oda 0000-0002-9431-1330; Tsuyoshi Nakagawa 0000-0003-1967-0445; Hiroki Mori 0000-0003-1967-0445; Iichiro Onishi 0000-0001-9744-0114; Tomoyuki Fujioka 0000-0002-7141-8901; Mio Mori 0000-0002-6107-4519; Kazunori Kubota 0000-0002-3240-4910; Ryoichi Hanazawa 0000-0002-4230-7356; Akihiro Hirakawa 0000-0003-2580-7460; Toshiaki Ishikawa 0000-0003-0102-8462; Kentaro Okamoto 0000-0002-1021-6417; Hiroyuki Uetake 0000-0001-7162-6842.
S-Editor:Zhang H
L-Editor:A
P-Editor:Zhang H
World Journal of Clinical Oncology2022年9期